
Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens
Sorana Segal-Maurer, MD, reviews research evaluating the efficacy of B/F/TAF compared with other HIV treatment regimens, including dolutegravir plus tenofovir/FTC.
Episodes in this series

BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following question(s):
- Studies have run head-to-head comparisons on the efficacy of B/F/TAF compared to other regimens, like dolutegravir + tenofovir/FTC, stressing patient adherence and the outcomes associated.
- What are the notable differences in efficacy were seen in these studies?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.